Rapamycin

Intro

Rapamycin (sirolimus) is a macrolide compound isolated in 1964 from Streptomyces hygroscopicus bacteria in Easter Island (Rapa Nui) soil — its name derives from the island.

FDA-approved in 1999 as Rapamune for solid organ transplant rejection prophylaxis, it inhibits mTOR (mechanistic target of rapamycin), the master growth and nutrient-sensing kinase conserved in all eukaryotes. Rapamycin forms a gain-of-function complex with FKBP12 that allosterically blocks mTORC1, preventing it from phosphorylating downstream targets. This induces autophagy (cellular cleanup), reduces protein synthesis, clears senescent cells, and modulates immune aging. No other pharmacological compound has extended lifespan across every eukaryotic organism tested — yeast, worms (C. elegans), flies (Drosophila), and mice — making it the most reproduced geroprotective intervention in aging biology. The NIA Interventions Testing Program (ITP) showed 9-14% lifespan extension in genetically heterogeneous mice started at 600 days (~60 years human equivalent); this is mouse data, not human. Off-label use in healthy adults for longevity is growing rapidly, supported by PEARL (2024, NCT04488601) — the first RCT in healthy normative-aging adults — and the Kaeberlein 2023 real-world dataset (n=333 off-label users). The prescribing physician community now includes dedicated longevity telehealth platforms and researchers who also use it personally.

Observed Effects

The PEARL trial (48-week RCT, healthy adults, 5 or 10 mg/week compounded) found no significant effect on visceral adiposity (primary endpoint, ηp²=0.001, p=0.942) but hit two positive secondary endpoints: lean tissue mass improvement in women at 10 mg/week compounded (ηp²=0.202, p=0.013) and pain reduction across all treated groups (ηp²=0.168, p=0.015). PEARL used compounded rapamycin — 10 mg compounded is approximately 2.86 mg generic sirolimus equivalent, a relevant distinction for interpreting the dosing context. A trend toward bone mineral density improvement was seen in men (ηp²=0.221, p=0.061) but did not reach significance. Kraig et al. 2018 RCT (ages 70-95, 3 months) showed improved CMV antibody response, confirming an immune function signal in older adults. A 2023 systematic review (Lancet Healthy Longevity, 19 studies) found positive effects on immune function (T-cell rejuvenation, vaccine response) and cardiovascular parameters in aging populations, with null findings in neurological, endocrine, and direct muscular outcomes. Bone resorption decreased (osteoclast inhibition via mTOR). Rheumatoid arthritis clinical improvement was documented via mTOR-Th17 pathway suppression. The Kaeberlein 2023 survey of 333 off-label users reported 80% perceived benefit — reduced illness frequency, better exercise recovery, improved skin quality — though these are self-reported, survivorship-biased, and cannot be disentangled from placebo. No human lifespan extension has been demonstrated; the ITP findings are in mice.

Field Reports

The first-year rapamycin experience has a recognizable arc: the first 6 weeks carry the highest side effect burden (mouth sores, dosing-day fatigue, mild glucose elevation), followed by improved tolerability, with subjective benefits typically emerging after 3-6 months for those who persist. Users who tolerate the first 3 months generally report a better long-term experience. Positive first-person reports cluster around sustained vitality, skin quality, fewer illness episodes, energy improvement in weeks 2-8, and joint discomfort reduction after 2-4 months; one self-experimenter documented DunedinPACE epigenetic-clock improvement over 12+ months, with confounders. Adverse-event reports are equally important: canker sores, pitting edema, fasting glucose 100-120 mg/dL in early months at 5 mg/week, progressive HbA1c rise resolving after stopping, and a re-challenge case where 'hollowed-out' mood plus heart-rate increase returned at a lower dose. A subset genuinely does not tolerate rapamycin at any dose. One woman aged 35 documented AMH decline after starting rapamycin — the most important women-specific adverse event in the community dataset. Metabolomics data from one user showed triglyceride and SDMA increases alongside taurine and cysteine increases, providing objective metabolic changes beyond subjective reporting. Discontinuation rate is meaningful — multiple users stop within 4-12 months due to intolerance — but community survivorship bias means this is undercounted. The cyclical mTOR management practice in advanced users (blunt with rapamycin → stimulate with resistance training and leucine → AMPK activation) represents the most sophisticated community protocol, designed to avoid chronic suppression of any single signaling arm.

Community Consensus

Rapamycin occupies a distinct niche in longevity practice: it is a prescription-only, physician-supervised intervention used primarily by adults aged 40-75 focused on healthspan extension, not by athletes or bodybuilders.

Its community skews toward educated professionals, longevity physicians, researchers, and data-oriented self-experimenters who track bloodwork and tolerability. Kaeberlein 2023 (n=333 self-selected users, mean dose 5.5 mg/week) is the anchor real-world dataset; 80% of users reported perceived benefit with a manageable adverse effect profile, but the cohort likely overrepresents people who tolerate rapamycin and remain engaged. The consensus is bullish but bounded: use it intermittently, monitor labs, respect dose holds, and do not confuse animal lifespan data with human proof. The community has three persistent misconceptions that matter clinically: (1) the Mannick 2014/2018 immune rejuvenation trials used everolimus, not rapamycin, so the immune findings require class-effect extrapolation; (2) the NIA ITP lifespan extension data is mouse data, not demonstrated human lifespan extension; and (3) transplant-dose immunosuppression should not be pasted onto weekly longevity dosing. At transplant doses (2-5 mg/day continuous), immunosuppression is real. At longevity doses (3-6 mg/week intermittent), weekly exposure is 7-35x lower and the net intent is immune modulation of immunosenescence rather than suppression of active immunity. The most sophisticated community contribution is the mTOR cycling frame: blunt mTOR for a defined window, then allow growth and repair signaling to reassert through training, nutrition, and drug holidays.

Risks & Monitoring

The most common adverse effect is aphthous ulcers (mouth sores), occurring in approximately 25% of users in the Kaeberlein 2023 dataset.

These typically peak in the first 6 weeks and often resolve with dose reduction, vitamin B12 supplementation (1-2 mg/day), or symptomatic treatment (Magic Mouthwash). Dosing-day fatigue starting 6-18 hours post-dose and lasting 24-48 hours is frequently reported across forums — consistent with rapamycin's half-life and its acute effect on mTOR-mitochondrial signaling. Fasting glucose elevation (documented at 100-120 mg/dL in the first few months in multiple self-reporters) is generally transient with weekly intermittent dosing; progressive HbA1c rise over months is a warning sign for mTORC2 involvement at the dose used and warrants dose reduction or stopping. Lipid changes — elevated LDL cholesterol and triglycerides — are confirmed across multiple studies including the 2023 systematic review; management includes dietary omega-3s or statins as needed. The adverse effect profile splits cleanly by mTOR complex: mTORC2 inhibition (the undesired effect) causes insulin resistance, dyslipidemia, and broader immunosuppression; it requires sustained continuous exposure (days to weeks) and is largely avoided with once-weekly dosing. At transplant doses (2-5 mg/day continuous), mTORC2 eventually becomes depleted, explaining why the transplant adverse effect profile is more severe than the longevity profile. Acne, upper respiratory infections, and elevated SDMA (kidney function marker) are documented but less common at standard longevity doses. A minority of users experience a 'hollowed-out' dysphoric feeling on dosing days that does not resolve with dose reduction — these individuals should stop. Wound healing impairment is real at any dose — stop rapamycin 2-4 weeks before elective surgery. In women of reproductive age, at least one community report documents AMH decline after starting rapamycin; mTOR involvement in folliculogenesis makes this biologically plausible. Rapamycin is teratogenic (FDA Category C/D) and absolutely contraindicated in pregnancy. Drug interactions are critical: strong CYP3A4 inhibitors (azole antifungals, clarithromycin) can raise sirolimus blood levels 5-20 fold; strong CYP3A4 inducers (rifampin, St. John's Wort, carbamazepine) lower them 50-90%. The transplant-dose immunosuppression concern is often cited against off-label use — at longevity doses (3-6 mg/week intermittent), weekly exposure is roughly 7-35x lower than transplant dosing, and the net effect is more accurately immune modulation than immunosuppression. Serious adverse events were not significantly elevated vs placebo in PEARL or Kraig trials at their tested doses and durations.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

For longevity and healthspan extension: 3-6 mg/week generic sirolimus, physician-supervised, with baseline bloodwork and quarterly monitoring.

Minimum commitment 6-12 months to assess tolerability and trend markers. For APOE4 carriers targeting Alzheimer's prevention: same protocol; the mTOR-autophagy-tau/amyloid clearance pathway provides the strongest mechanistic case; one observational physician cohort reports no progression in high-risk patients, but this is uncontrolled and not proof of prevention. For immune rejuvenation in older adults: 3-6 mg/week; time vaccinations 2 weeks after the last dose, not before. The rapalog everolimus (not rapamycin) was used in the Mannick immune rejuvenation trials — a class-effect extrapolation to rapamycin is plausible but unproven. For cardiovascular risk reduction as part of a broader program: 3-6 mg/week alongside lipid management; the systematic review positive cardiovascular signal (2023) and dog-aging cardiac data support this use, but no human RCT endpoint data exists. For women targeting lean mass or pain reduction: PEARL's secondary data specifically supports a women-only lean mass benefit at 10 mg/week compounded (≈2.86 mg generic) — this dose is the current best-supported target for women with this goal. For the cyclical mTOR management approach practiced by advanced community users: rapamycin for 3-4 months (weekly, blunt phase) → drug holiday 1-2 months with emphasis on resistance training and leucine-rich diet (stimulate phase) → optional AMPK activation phase (exercise, metformin, berberine). This cycling framework aims to avoid chronic suppression of anabolic signaling while periodically clearing senescent cells and inducing autophagy.

Dosing Details

The standard longevity dosing approach is 3-6 mg/week generic sirolimus as a single weekly dose, titrated from a low starting point.

Most physicians begin at 1-3 mg/week and increase by 1 mg every 2-4 weeks based on tolerability. A common physician-supervised pattern is 1-2 mg/week to start, increasing to 4-6 mg/week over 4-8 weeks, taken once weekly with food and preferably on a low-exposure day. Experienced community practice tends to converge at 3-5 mg/week, with 2-3 mg/week as the cautious start. A critical formulation distinction: PEARL used compounded rapamycin, where 10 mg compounded is approximately equivalent to 2.86 mg generic sirolimus due to differing bioavailability. Do not compare doses without specifying formulation. Blood monitoring: sirolimus trough level after 4-6 weeks on stable dose; longevity target 3-15 ng/mL (vs 4-20 ng/mL for transplant). Grapefruit co-administration (half a grapefruit 30-60 min before dose) inhibits CYP3A4 and raises bioavailability 1.5-3 fold — used by many community members to effectively increase exposure without increasing pill count, but requires blood level monitoring to avoid over-dosing. Fringe high-pulse protocols (20-30 mg/month, monthly) exist in the community but are controversial and carry higher mTORC2 disruption risk. Timing rules: stop 2-4 weeks before elective surgery; skip the dose the week of any vaccination (ideally 2 weeks); separate weekly dose from heavy resistance training by 48 hours to preserve the post-exercise anabolic window. CYP3A4 inducers (St. John's Wort, rifampin) lower rapamycin levels 50-90%; inhibitors (azole antifungals, clarithromycin) raise them 5-20 fold — always review new medications for CYP3A4 effects.

Stacks & Alternatives

Dual mTOR pathway inhibition — rapamycin blocks mTORC1 directly; metformin activates AMPK, which inhibits mTORC1 upstream via TSC2. Metformin also mitigates rapamycin-associated glucose dysregulation in metabolically vulnerable patients. Used by some longevity physicians for high-risk patients. NIA ITP: metformin + rapamycin showed additive lifespan extension in mice.

NIA ITP showed acarbose alone extends lifespan; acarbose + rapamycin produced additive lifespan extension. Alpha-glucosidase inhibitor reduces post-prandial glucose spikes, directly mitigating rapamycin-associated glucose dysregulation.

Complementary mechanisms: rapamycin prevents senescent cell accumulation (via autophagy induction and SASP suppression); D+Q clears already-accumulated senescent cells. The two approaches address different aspects of the senescence burden.

Mitigate rapamycin-associated LDL and triglyceride elevation. EPA and DHA reduce triglycerides and have favorable effects on LDL particle size. Routine add-on for patients who develop lipid changes.

Alternatives

Stack Cost

Practical Setup

Rapamycin requires physician supervision and is not appropriate for self-directed use — the drug interaction risks (CYP3A4), the need for blood level monitoring, and the metabolic adverse effects all require medical oversight.

Start with baseline bloodwork: fasting glucose, HbA1c, comprehensive metabolic panel, lipid panel, and CBC. Women of reproductive age should add AMH at baseline. Establish a monitoring schedule of repeat labs at 12 weeks, then every 6-12 months; add sirolimus blood trough level at 6 weeks on stable dose. The compounded vs generic formulation distinction is clinically critical: 10 mg compounded rapamycin ≈ 2.86 mg generic sirolimus per PEARL trial formulation analysis — never compare doses without specifying formulation. Medication and monitoring costs vary by formulation, insurance, pharmacy, and lab cadence. Drug holidays are required before elective surgery (stop 2-4 weeks prior, restart 4-6 weeks post-op after wound closure) and for vaccinations (skip the dose week of any vaccine, ideally 2 weeks). Avoid concurrent use with St. John's Wort (powerful CYP3A4 inducer, commonly overlooked when taken for depression) and azole antifungals. Grapefruit co-administration is practiced in the community to boost bioavailability 1.5-3 fold via CYP3A4 inhibition, but requires blood level monitoring to avoid over-exposure. The 48-hour rule for resistance training (dose at least 48h before heavy training to preserve the post-exercise mTOR-S6K1 anabolic window) is used by multiple longevity clinicians. For users starting rapamycin, the realistic first-year expectation is: possible early tolerability challenges (weeks 1-6), stabilization (weeks 6-12), potential early benefits (months 3-6), with longer-term biological effects requiring at least 12 months of monitoring to assess. Discontinue and reassess if: progressive HbA1c elevation >0.3 percentage points over 3-6 months, fasting glucose repeatedly >126 mg/dL, recurrent serious infections, intractable adverse effects, or pregnancy.

Mechanism Deep Dive

Rapamycin binds intracellular FKBP12 (FK506-binding protein 12); the rapamycin-FKBP12 complex then occupies the FRB (FKBP12-rapamycin binding) domain of mTOR, allosterically inhibiting mTORC1 substrate recruitment.

This is not a direct catalytic inhibitor — it prevents mTORC1 from phosphorylating downstream substrates rather than blocking the kinase active site directly. Two key downstream targets: S6K1 (ribosomal S6 kinase 1), which drives ribosome biogenesis and protein synthesis when activated by mTORC1; and 4E-BP1 (eIF4E-binding protein 1), which releases eIF4E for cap-dependent mRNA translation when phosphorylated. Rapamycin blocks both, reducing anabolic protein synthesis, especially in proliferating cells. Third key target: ULK1 (autophagy initiator), which is normally suppressed by mTORC1 phosphorylation at Ser757. Rapamycin releases ULK1 → autophagosome formation initiates → cellular cleanup of damaged organelles (dysfunctional mitochondria via mitophagy), misfolded proteins, and senescent cell components proceeds. There is also a S6K1 feedback loop: S6K1 normally phosphorylates IRS-1 at inhibitory sites as negative feedback on insulin signaling. Rapamycin's S6K1 inhibition removes this feedback, potentially upregulating upstream Akt signaling — explaining why acute rapamycin treatment can paradoxically improve insulin sensitivity while chronic continuous dosing at high doses impairs it (mTORC2 depletion). The critical mTORC1/mTORC2 selectivity: mTORC1 (raptor subunit) is acutely rapamycin-sensitive; mTORC2 (rictor subunit) regulates Akt-Ser473, SGK1, and PKCα (cell survival, cytoskeletal organization, metabolic homeostasis) and is largely rapamycin-resistant at standard doses. mTORC2 disruption requires depleting the free mTOR pool available for mTORC2 complex assembly — this takes days to weeks of continuous rapamycin exposure. Once-weekly intermittent dosing allows the free mTOR pool to regenerate between doses, largely sparing mTORC2. This is the mechanistic basis for the community's strong preference for intermittent dosing ('blunting mTOR, not abolishing it'). Senescence effects: mTORC1 inhibition reduces SASP (the pro-inflammatory secretome of senescent cells) by suppressing NF-κB-mediated inflammatory gene expression and reducing p21 translation. Mouse data shows reduced p16+/p21+ senescent cell accumulation in multiple tissues. Immunological aging: rapamycin (and rapalogs in clinical trials) reverses features of immunosenescence in old mice and humans — naive T-cell pool expands, memory formation improves, antibody responses to vaccination increase. The evolutionary rationale: mTOR is optimized for driving growth and reproduction across eukaryotic life — there is no evolutionary selection pressure to reduce it post-reproduction. Chronically elevated post-reproductive mTOR drives aging hallmarks. Intermittent pharmacological blunting of mTOR may partially address what evolution never selected against.

Evidence Index